Protagonist Therapeutics (PTGX) - 5.08% Below 52-Week High: Buy or Wait?

Stock Details

Protagonist Therapeutics Inc (PTGX), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $152.64. Over the past 52 weeks, it has ranged between $54.50 and $160.81. This places the current price at 94.9% of its 52-week high and 180.1% above its 52-week low. Recent trading volume was recorded at 664,526. The 14-day Relative Strength Index (RSI) stands at 56.99, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $135.92 by 12.30%. Similarly, it is above its 200-day moving average of $103.49 by 47.49%. The MACD histogram is -0.48, indicating bearish momentum (MACD Line: 5.74, Signal Line: 6.22). There are currently 2 active alerts set for PTGX by users.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

148.77

Above market average

Forward P/E

38.61

Earnings expected to grow

PEG Ratio

0.00

Potentially undervalued

Price to Book

11.87

EV/EBITDA

153.92

EPS (TTM)

$1.04

Price to Sales

35.50

Beta

1.79

More volatile than market

Q:How is PTGX valued relative to its earnings and growth?

Protagonist Therapeutics Inc trades at a P/E ratio of 148.77, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 38.61 is lower than the current P/E, indicating analysts expect earnings to grow over the next year.0

Q:What is PTGX's risk profile compared to the market?

With a beta of 1.79, Protagonist Therapeutics Inc is significantly more volatile than the market. For every 10% market move, this stock tends to move 18% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 11.87 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

29.40%

Operating Margin

74.40%

EBITDA

$59.88M

Return on Equity

11.00%

Return on Assets

4.55%

Revenue Growth (YoY)

3749.00%

Earnings Growth (YoY)

351.30%

Q:How profitable and efficient is PTGX's business model?

Protagonist Therapeutics Inc achieves a profit margin of 29.40%, meaning it retains $29.40 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 74.40% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 11.00% and ROA at 4.55%, the company achieves moderate returns on invested capital.

Q:What are PTGX's recent growth trends?

Protagonist Therapeutics Inc's revenue grew by 3749.00% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 351.30% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$10.0B

Revenue (TTM)

$281.99M

Revenue/Share (TTM)

$4.36

Shares Outstanding

64.71M

Book Value/Share

$13.01

Asset Type

Common Stock

Q:What is PTGX's market capitalization and position?

Protagonist Therapeutics Inc has a market capitalization of $10.0B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 64.71M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.

Q:How does PTGX's price compare to its book value?

Protagonist Therapeutics Inc's book value per share is $13.01, while the current stock price is $152.64, resulting in a price-to-book (P/B) ratio of 11.73. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$170.38

11.62% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for PTGX?

13 analysts cover PTGX with 92% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $170.38 implies 11.6% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on PTGX?

Current analyst recommendations:3 Strong Buy, 9 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 26, 2026, 02:12 AM

Technical Indicators

RSI (14-day)

56.99

Neutral

50-Day Moving Average

$135.92

12.30% above MA-50

200-Day Moving Average

$103.49

47.49% above MA-200

MACD Line

5.74

MACD Signal

6.22

MACD Histogram

-0.48

Bearish

Q:What does PTGX's RSI value tell investors?

The RSI (Relative Strength Index) for PTGX is currently 56.99, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.

Q:How should traders interpret PTGX's MACD and moving average crossovers?

MACD analysis shows the MACD line at 5.74 below the signal line at 6.22, with histogram at -0.48. This bearish crossover indicates downward pressure. The 50-day MA ($135.92) is above the 200-day MA ($103.49), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Aug 26, 2026, 12:33 AM

Condition	Threshold	Created At
Forward P/E falls below	31.83 x	Aug 13, 2026, 01:34 PM
Price decreases by	10%	Aug 13, 2026, 01:34 PM

Condition

Threshold

Created At

Forward P/E falls below

31.83 x

Aug 13, 2026, 01:34 PM

Price decreases by

10%